An observational study in Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures), sponsored by Beijing Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Beijing Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Hip Fractures with a site in China — 15 open to participants now, 16 under way, none of them phase 3. Hip Fractures · China.
Among the 51 studies in Hip Fractures with a site in China, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 10 that started in 2024, is one of 17 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 50th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →15 of the 51 studies in Hip Fractures with a site in China are open now. Recruiting first, the newest first:
Beijing Jishuitan Hospital · Sites in China
Ages 18–80
Wenzhou Medical University · Sites in China
Ages 60+
Shanghai Geriatric Medical Center · Sites in China
Ages 65+
Peking University Shenzhen Hospital · Sites in China
Ages 65+
Huazhong University of Science and Technology · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3 · Phase 4 5
First in 2008; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 149 across 280 observational studies indexed under Hip Fractures.
Median enrollment 110 across the 34 interventional studies, 600 across the 17 observational. Of the 22 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 51 have an industry lead sponsor. The 10 most frequent:
Beijing Hospital is the lead sponsor of 52 studies on the registry; 24 are open to participants now.
Beijing Hospital has 1 study filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
3 of the studies in Hip Fractures with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07301242Shanghai Geriatric Medical CenterPopulation Pharmacokinetics and Pharmacodynamics of Ciprofol | 2026-11 |
| NCT03116490Wenzhou Medical UniversityThe Effects of Anesthesia Type on the Prognosis of Hip Fracture Surgery on Elderly Patients | 2026-12 |
| NCT06728033West China HospitalFascia Iliaca Compartment Block and Tramadol for Analgesia in Hip Fracture | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Hip Fractures with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To address the difficulties and problems currently facing large-scale clinical cohort studies in China, and on the basis of the existing project "Construction of Clinical Registration Database and Risk Assessment System for Osteoporosis and Osteoarthritis" under the National Key R\&D Program of the Ministry of Science and Technology, this project aims to target elderly hip fracture-an international public health issue-by collaborating with 38 hospitals across the country to jointly establish the largest specialized cohort for elderly hip fracture in China, thereby providing a data platform and technical support for multicenter clinical cohort studies on elderly hip fracture.
Hip fracture inpatients at grade-A tertiary hospitals across China
Inclusion Criteria:1: The subjects are of Chinese nationality.
2: The subject is 60 years of age or older (including the boundary value)
3:The subject has been diagnosed with hip fracture by imaging, including femoral neck fracture, intertrochanteric fracture of femur, and subtrochanteric fracture of femur
4: Patients who were hospitalized for hip fracture treatment (surgical or conservative) after September 1, 2022
5: The subject can fully understand and sign the form.
-
Exclusion Criteria:1: Pathological fractures caused by primary or tumors of bone or bone developmental disorders
2: Patients with peri-implant fractures or polytrauma (multiple injuries resulting from a single traumatic event in which two or more anatomical sites in the body are severely injured, with one of them being severely injured even in the absence of the traumatic event also posing a life-threatening risk)
3: Subjects who, in the opinion of the investigator, are not eligible for enrollment in the study.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A cohort of elderly patients with hip fracture
death
Post-hip fracture mortality (yes/no)
Time frame: Six months, one year, and two years after hip fracture
Clavien-Dindo classification of complications
Clavien-Dindo classification of complications
Time frame: Six months, one year, and two years after hip fracture
Conservative treatment status for patients managed non-surgically
Conservative treatment status for patients managed non-surgically
Time frame: Six months, one year, and two years after hip fracture
Imaging data
Imaging data
Time frame: one day,Six months, one year, and two years after hip fracture
Other new adverse events
Other new adverse events
Time frame: Six months, one year, and two years after hip fracture
Place of residence at follow-up.
Place of residence at follow-up.
Time frame: Six months, one year, and two years after hip fracture
Post-hospital care
Post-hospital care
Time frame: Six months, one year, and two years after hip fracture
Anti-osteoporosis treatment status
Anti-osteoporosis treatment status
Time frame: Six months, one year, and two years after hip fracture
EQ-5D Quality of Life score
EQ-5D Quality of Life score
Time frame: Six months, one year, and two years after hip fracture
Time to discontinuation of strict bed rest
Time to discontinuation of strict bed rest
Time frame: Six months, one year, and two years after hip fracture
Refracture event
Refracture event
Time frame: Six months, one year, and two years after hip fracture
FAC Functional Walking Scale
FAC Functional Walking Scale
Time frame: Six months, one year, and two years after hip fracture
Plan to share: Yes — De-identified individual participant data (IPD) from this nationwide multicenter prospective cohort of elderly patients with hip fracture will be shared. The shared dataset includes: (1) demographic and baseline characteristics (age, sex, comorbidities, frailty and functional status); (2) injury and treatment details (fracture type, surgical procedure, anesthesia method, timing of surgery); (3) perioperative management data (blood transfusion, rehabilitation); and (4) outcome data at each follow-up time point (mortality, complications, reoperation, functional scores such as FAC or EQ-5D, and quality of life). All direct identifiers (name, ID number, phone, address, hospital record number) will be removed before sharing. Data from individual centers will be pooled after harmonization across sites.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: The study protocol and statistical analysis plan are available immediately upon study registration. De-identified IPD and the analytic code will be available within 1 year after publication of the primary outcome results in a peer-reviewed journal, and will remain available for at least 5 years after the final study report is submitted.
Access criteria: Access will be open to researchers from academic institutions, hospitals, or public health organizations worldwide with a methodologically sound research proposal consistent with the original informed consent. To request access, researchers should submit a proposal (including research question, analysis plan, and publication plan) to the corresponding author / coordinating center by email. Proposals will be reviewed by the study steering committee within 30 days. Approved researchers will be required to sign a data use agreement stipulating that data will be used only for the approved purpose, will not be redistributed, and that results will be shared with the study group before publication. De-identified data will be transferred through a secure file-sharing platform.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 107 non-industry observational studies under Hip Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 65. This study's planned 36 months is above that.
Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 12 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Hospital